As the shutdown drags out, there could be delays in regulatory processes and payments for medical services as well as the ...

Having expanded access to quantitative hemoglobin variant testing in 40 countries, Hemex is now also setting its sights on the US and Europe.

Researchers hope to soon commercialize a simple, inexpensive, and accessible screening test that uses taste as a detection ...

Regulatory burdens have raised the capital requirements for early-stage companies, causing many to do what would have been ...

The company said that its low-cost, high-throughput four-plex test could help to identify type 1 diabetes patients sooner and inform treatments to delay progression.

An explosion in Medicare spending on epilepsy testing resembles a pattern of improper payments for genetic testing that was ...

Sebia sells electrophoresis instruments and protein-based IVDs for use in multiple myeloma as well as metabolic, autoimmune, and inflammatory conditions.

The University of Washington spinout's test is used to detect and analyze protein biomarkers in a low-cost test, with results in 15 minutes.

The firms intend to comarket genomic solutions combining clinical decision support and genomic workflow integration with microarray testing.

Saliva, sweat, and interstitial fluid have shown promise as alternative sample types in situations where blood may be too hard to access.

The test is intended for patients ages 55 and older presenting with signs, symptoms, or complaints of cognitive decline.

Last week, readers were most interested in a story about Meridian Bioscience's two-pronged approach to fuel its success.